Restoring Health at the Source: Dr. Linda Black on the Future of Regenerative Veterinary Care

Gallant CEO Dr. Linda Black, DVM, PhD, recently spoke with Veterinary Advantage about why ready-to-use, allogeneic stem cell therapy for pets is becoming a practical new tool in veterinary medicine. In the Q&A, Dr. Black explains that regenerative medicine isn’t about masking symptoms—it’s about restoring healthy function by addressing the biology that drives disease in the first place.

From Veterinary Advantage
Restoring Health at the Source: Q&A With Dr. Linda Black DVM, PhD

A central focus of the conversation is inflammation. Many chronic conditions veterinarians see every day are fueled by immune dysfunction and persistent inflammatory signaling. Dr. Black points to diseases like osteoarthritis, canine atopic dermatitis, feline chronic kidney disease (CKD), and refractory feline chronic gingivostomatitis (FCGS) as examples where inflammation keeps patients stuck in cycles of pain or flare-ups. Mesenchymal stem cells (MSCs) offer a disease-modifying approach by helping rebalance immune responses and supporting tissue repair, aiming to treat disease at its source rather than simply managing clinical signs.

Dr. Black also highlights why Gallant is moving beyond traditional autologous stem cell procedures. Autologous approaches require harvesting cells from the patient, outside processing, anesthesia, and can vary in quality. Gallant’s off-the-shelf stem cell therapies for cats and dogs are donor-derived MSC products manufactured under FDA drug standards, frozen for shipment, and thawed in-clinic for simple IV administration. The goal is consistent, scalable regenerative care that fits into real-world practice.

Looking ahead, Dr. Black shared that Gallant’s lead investigational therapy for refractory FCGS remains on track for conditional FDA approval in early 2026, with additional programs advancing for OA, atopic dermatitis, and feline CKD. Her outlook is clear: as FDA-reviewed, ready-to-use cell therapies reach clinics, regenerative medicine can shift from a niche option to a mainstream standard of care.